Agios Pharmaceuticals Inc (NASDAQ:AGIO) had its Hold rating reiterated by Cann

Analyst Ratings For Agios Pharmaceuticals Inc (NASDAQ:AGIO)

Story continues below

Today, Cann reiterated its Hold rating on Agios Pharmaceuticals Inc (NASDAQ:AGIO).

There are 8 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Agios Pharmaceuticals Inc (NASDAQ:AGIO) is Buy with a consensus target price of $99.4444 per share, a potential 19.96% upside.

Some recent analyst ratings include

  • 9/5/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) had its Hold rating reiterated by Cann
  • 9/5/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) had its Buy rating reiterated by Canaccord Genuity with a $90.00 price target
  • 8/2/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) had its Buy rating reiterated by Needham & Company LLC
  • 7/23/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) had its Buy rating reiterated by SunTrust Banks with a $123.00 price target
  • 5/23/2018-Agios Pharmaceuticals Inc (NASDAQ:AGIO) has coverage initiated with a Buy rating and $117.00 price target

Recent Insider Trading Activity For Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Agios Pharmaceuticals Inc (NASDAQ:AGIO) has insider ownership of 3.02% and institutional ownership of 93.64%.

  • On 8/30/2018 Christopher Bowden, Insider, sold 1,700 with an average share price of $80.03 per share and the total transaction amounting to $136,051.00.
  • On 8/24/2018 Steven L Hoerter, Insider, sold 2,050 with an average share price of $74.92 per share and the total transaction amounting to $153,586.00.
  • On 8/6/2018 Scott Biller, Insider, sold 3,000 with an average share price of $80.11 per share and the total transaction amounting to $240,330.00.
  • On 7/25/2018 Steven L Hoerter, Insider, sold 2,050 with an average share price of $84.58 per share and the total transaction amounting to $173,389.00.
  • On 7/9/2018 Carman Alenson, Insider, sold 272 with an average share price of $84.94 per share and the total transaction amounting to $23,103.68.
  • On 7/5/2018 Scott Biller, Insider, sold 3,000 with an average share price of $83.50 per share and the total transaction amounting to $250,500.00.
  • On 6/22/2018 Steven L Hoerter, Insider, sold 2,050 with an average share price of $97.58 per share and the total transaction amounting to $200,039.00.

About Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Recent Trading Activity for Agios Pharmaceuticals Inc (NASDAQ:AGIO)
Shares of Agios Pharmaceuticals Inc closed the previous trading session at 82,95 up +1,81 2,23 % with 85 shares trading hands.

An ad to help with our costs